Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Poliovirus Vaccine Market by Type (Inactivated Polio Vaccine (IPV), Oral Polio Vaccine (OPV)), By Application (Public, Private) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Poliovirus Vaccine Market by Type (Inactivated Polio Vaccine (IPV), Oral Polio Vaccine (OPV)), By Application (Public, Private) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 207221 3300 Pharma & Healthcare 377 248 Pages 4.8 (32)
                                          

Market Overview:


The global poliovirus vaccine market is expected to grow at a CAGR of 6.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of polio, increasing government initiatives for vaccination, and growing demand for oral polio vaccine (OPV). However, the high cost of vaccines and lack of awareness about vaccinations are some factors that could hamper the growth of this market. The global poliovirus vaccine market is segmented on the basis of type, application, and region. On the basis of type, it is divided into inactivated polio vaccine (IPV) and oral polio vaccine (OPV). OPV is further classified into monovalent OPV and bivalent OPV. On the basis of application, it is segmented into public sector and private sector. Regionally, it is analyzed across North America, Latin America Europe Asia Pacific Middle East & Africa (MEA).


Global Poliovirus Vaccine Industry Outlook


Product Definition:


A vaccine used to prevent poliomyelitis, an acute viral disease that may cause paralysis. The vaccine is made from a killed virus and is given by injection.


Inactivated Polio Vaccine (IPV):


Inactivated Polio Vaccine (IPV) is a vaccine that prevents poliomyelitis. It's created by heating the virus in the laboratory to kill all of its harmful components, so it can't cause disease. The vaccine was first used in 1955 and has been continually updated since then to make sure it contains all of the active ingredients needed to prevent disease.


The World Health Organization (WHO).


Oral Polio Vaccine (OPV):


Oral polio vaccine (OPV) is a live, attenuated virus vaccine used to prevent disease caused by the Poliovirus. It was first introduced in England and Wales in 1988 and since then it has been widely used across the world especially in developing countries like India, Brazil, etc. OPV is an inexpensive vaccine as compared to its counterparts; however, there are no licensed commercial vaccines for poliomyletis that are available commercially today.


Application Insights:


Public health application of poliovirus vaccines accounted for the largest share of more than 60.0% in 2017. This is attributed to the global eradication of wild polio viruses and complete cessation of transmission from 1988 to 2005 due to implementation of the Global Polio Eradication Initiative (GPEI). The GPEI was a joint effort by WHO, national governments, international organizations and donor countries to stop the spread of wild poliovirus globally.


The use in immunization against vaccine-derived poliomyelitis has declined since its introduction as an alternative method for controllingpolio incidence through vaccination campaigns using OPV or IPV doses multiple times at intervals that are sufficient for immunity against infection with type 1 virus or residuals thereof (maintenance immunization). As a result, usage rates have declined significantly over past few years across all age groups below 5 years which may hinder market growth over forecast period.


Regional Analysis:


The global poliovirus vaccine market is dominated by the North American region, which accounted for a share of over 60.0% in 2017. This can be attributed to the fact that most of the countries in this region have been polio-free since last three years and are thus considered as high-risk areas for transmission of this virus. Moreover, government initiatives coupled with high healthcare expenditure levels in this region are some other factors contributing toward a large market share of North America.


However, Asia Pacific is anticipated to grow at an exponential rate throughout the forecast period owing to increasing number of reported cases across various countries such as India and Pakistan and low vaccination coverage especially among children below 5 years old. In addition, lack of awareness about these vaccines among parents will also boost growth during the forecast period along with continuous government efforts towards its distribution through mass media advertising campaigns etc., which has resulted into higher revenue generation from Asian markets compared to other regions over past few years (Table 1).


Growth Factors:


  • Increasing incidence of poliomyelitis across the globe
  • Growing awareness about the benefits of vaccination against polio
  • Rising demand for safe and effective vaccines
  • Technological advancements in vaccine development and production processes
  • increasing government funding for polio vaccine research and development

Scope Of The Report

Report Attributes

Report Details

Report Title

Poliovirus Vaccine Market Research Report

By Type

Inactivated Polio Vaccine (IPV), Oral Polio Vaccine (OPV)

By Application

Public, Private

By Companies

Sanofi, GSK, Bibcol, Serum Institute, Tiantan Biological, IMBCA, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

248

Number of Tables & Figures

174

Customization Available

Yes, the report can be customized as per your need.


Global Poliovirus Vaccine Market Report Segments:

The global Poliovirus Vaccine market is segmented on the basis of:

Types

Inactivated Polio Vaccine (IPV), Oral Polio Vaccine (OPV)

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Public, Private

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Sanofi
  2. GSK
  3. Bibcol
  4. Serum Institute
  5. Tiantan Biological
  6. IMBCA
  7. Panacea Biotec Ltd
  8. Bio-Med
  9. Halfkin Bio-Pharmaceuticals

Global Poliovirus Vaccine Market Overview


Highlights of The Poliovirus Vaccine Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Inactivated Polio Vaccine (IPV)
    2. Oral Polio Vaccine (OPV)
  1. By Application:

    1. Public
    2. Private
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Poliovirus Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Poliovirus Vaccine Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Poliovirus vaccine is a vaccine that helps protect against poliovirus. It is made from dead or weakened viruses and is given by injection. Poliovirus vaccine can help prevent polio, a serious childhood illness.

Some of the key players operating in the poliovirus vaccine market are Sanofi, GSK, Bibcol, Serum Institute, Tiantan Biological, IMBCA, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals.

The poliovirus vaccine market is expected to register a CAGR of 6.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Poliovirus Vaccine Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Poliovirus Vaccine Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Poliovirus Vaccine Market - Supply Chain
   4.5. Global Poliovirus Vaccine Market Forecast
      4.5.1. Poliovirus Vaccine Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Poliovirus Vaccine Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Poliovirus Vaccine Market Absolute $ Opportunity

5. Global Poliovirus Vaccine Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Poliovirus Vaccine Market Size and Volume Forecast by Type
      5.3.1. Inactivated Polio Vaccine (IPV)
      5.3.2. Oral Polio Vaccine (OPV)
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Poliovirus Vaccine Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Poliovirus Vaccine Market Size and Volume Forecast by Application
      6.3.1. Public
      6.3.2. Private
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Poliovirus Vaccine Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Poliovirus Vaccine Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Poliovirus Vaccine Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Poliovirus Vaccine Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Poliovirus Vaccine Demand Share Forecast, 2019-2026

9. North America Poliovirus Vaccine Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Poliovirus Vaccine Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Poliovirus Vaccine Market Size and Volume Forecast by Application
      9.4.1. Public
      9.4.2. Private
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Poliovirus Vaccine Market Size and Volume Forecast by Type
      9.7.1. Inactivated Polio Vaccine (IPV)
      9.7.2. Oral Polio Vaccine (OPV)
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Poliovirus Vaccine Demand Share Forecast, 2019-2026

10. Latin America Poliovirus Vaccine Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Poliovirus Vaccine Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Poliovirus Vaccine Market Size and Volume Forecast by Application
      10.4.1. Public
      10.4.2. Private
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Poliovirus Vaccine Market Size and Volume Forecast by Type
      10.7.1. Inactivated Polio Vaccine (IPV)
      10.7.2. Oral Polio Vaccine (OPV)
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Poliovirus Vaccine Demand Share Forecast, 2019-2026

11. Europe Poliovirus Vaccine Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Poliovirus Vaccine Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Poliovirus Vaccine Market Size and Volume Forecast by Application
      11.4.1. Public
      11.4.2. Private
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Poliovirus Vaccine Market Size and Volume Forecast by Type
      11.7.1. Inactivated Polio Vaccine (IPV)
      11.7.2. Oral Polio Vaccine (OPV)
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Gowth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Poliovirus Vaccine Demand Share, 2019-2026

12. Asia Pacific Poliovirus Vaccine Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Poliovirus Vaccine Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Poliovirus Vaccine Market Size and Volume Forecast by Application
      12.4.1. Public
      12.4.2. Private
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Poliovirus Vaccine Market Size and Volume Forecast by Type
      12.7.1. Inactivated Polio Vaccine (IPV)
      12.7.2. Oral Polio Vaccine (OPV)
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Poliovirus Vaccine Demand Share, 2019-2026

13. Middle East & Africa Poliovirus Vaccine Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Poliovirus Vaccine Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Poliovirus Vaccine Market Size and Volume Forecast by Application
      13.4.1. Public
      13.4.2. Private
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Poliovirus Vaccine Market Size and Volume Forecast by Type
      13.7.1. Inactivated Polio Vaccine (IPV)
      13.7.2. Oral Polio Vaccine (OPV)
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Poliovirus Vaccine Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Poliovirus Vaccine Market: Market Share Analysis
   14.2. Poliovirus Vaccine Distributors and Customers
   14.3. Poliovirus Vaccine Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Sanofi
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. GSK
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Bibcol
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Serum Institute
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Tiantan Biological
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. IMBCA
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Panacea Biotec Ltd
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Bio-Med
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Halfkin Bio-Pharmaceuticals
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us